Lupin is currently trading at Rs. 756.35, up by 5.10 points or 0.68 % from its previous closing of Rs. 751.25 on the BSE.
The scrip opened at Rs. 755.00 and has touched a high and low of Rs. 764.70 and Rs. 749.60 respectively. So far 16828 shares were traded on the counter.
The BSE group ‘A’ stock of face value Rs. 2 has touched a 52 week high of Rs. 971.30 on 13-Jan-2022 and a 52 week low of Rs. 583.05 on 25-May-2022.
Last one week high and low of the scrip stood at Rs. 762.95 and Rs. 718.00 respectively. The current market cap of the company is Rs. 34680.04 crore.
The promoters holding in the company stood at 47.11 % while Institutions and Non-Institutions held 41.44 % and 11.45 % respectively.
Lupin has launched Regional Reference Laboratory in Indore, Madhya Pradesh, as part of its expansion in Central India. Lupin Diagnostics currently operates over 325 LupiMitra (Lupin’s franchise collection centers) and 23 laboratories in India.
The expansion in Indore is well-aligned with Lupin Diagnostics’ commitment to improving access to high-quality, reliable, and advanced testing centres and home collection facilities at an affordable price.
In addition to routine and specialized tests, Lupin Diagnostics also offers molecular diagnostics, cytogenetics, flow cytometry, cytology, microbiology, serology, hematology, immunology, routine biochemistry and many more. These labs are equipped with qualified clinical experts and automated, streamlined processes so patients can make informed decisions about their health.
Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.